GIP
ACRS icon

Granite Investment Partners’s Aclaris Therapeutics ACRS Stock Holding History

Granite Investment Partners’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-8,230
Closed -$164K – 320
2018
Q2 		$164K Buy
+8,230
New +$152K 0.01% 304
2018
Q1 		– Sell
-22,914
Closed -$565K – 300
2017
Q4 		$565K Buy
+22,914
New +$558K 0.04% 267

Other funds holding ACRS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Granite Investment Partners's ACRS Position: Q3 2018 in Review

Granite Investment Partners sold out of Aclaris Therapeutics (ACRS) in Q3 2018, closing a stake of 8,230 shares — an estimated $164K sold.

Granite Investment Partners first reported a position in ACRS in Q4 2017 and held it in 2 quarters. The position peaked at $565K in Q4 2017. 86 funds tracked by Wall St. Rank hold ACRS as of Q3 2018.

  • Granite Investment Partners reported no remaining Aclaris Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Granite Investment Partners sold 8,230 Aclaris Therapeutics shares in Q3 2018, an estimated $164K.
  • Granite Investment Partners first reported a position in Aclaris Therapeutics in Q4 2017 and held it in 2 quarters.
  • Granite Investment Partners's Aclaris Therapeutics position peaked at $565K in Q4 2017.
  • 86 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2018.

Based on Granite Investment Partners's 13F filing for Q3 2018, filed 8 Nov 2018.